company background image
PCRX

Pacira BioSciences NasdaqGS:PCRX Stock Report

Last Price

US$39.40

Market Cap

US$1.8b

7D

10.9%

1Y

-35.9%

Updated

29 Jan, 2023

Data

Company Financials +

Pacira BioSciences, Inc.

NasdaqGS:PCRX Stock Report

Mkt Cap: US$1.8b

PCRX Stock Overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States.

PCRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health2/6
Dividends0/6

My Notes

New

Notes are coming soon

Pacira BioSciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pacira BioSciences
Historical stock prices
Current Share PriceUS$39.40
52 Week HighUS$82.16
52 Week LowUS$35.35
Beta0.83
1 Month Change2.05%
3 Month Change-23.88%
1 Year Change-35.94%
3 Year Change-8.84%
5 Year Change2.34%
Change since IPO461.25%

Recent News & Updates

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Recent updates

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04
These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Nov 29
Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Oct 15
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

We Wouldn't Rely On Pacira BioSciences' (NASDAQ:PCRX) Statutory Earnings As A Guide

Feb 16
We Wouldn't Rely On Pacira BioSciences' (NASDAQ:PCRX) Statutory Earnings As A Guide

Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 29
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Latest Stock Performance A Reflection Of Its Financial Health?

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Jan 11
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Need To Know: Pacira BioSciences, Inc. (NASDAQ:PCRX) Insiders Have Been Selling Shares

Dec 23
Need To Know: Pacira BioSciences, Inc. (NASDAQ:PCRX) Insiders Have Been Selling Shares

Do Pacira BioSciences's (NASDAQ:PCRX) Earnings Warrant Your Attention?

Dec 08
Do Pacira BioSciences's (NASDAQ:PCRX) Earnings Warrant Your Attention?

Shareholder Returns

PCRXUS PharmaceuticalsUS Market
7D10.9%-1.4%2.8%
1Y-35.9%4.5%-9.2%

Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned 4.5% over the past year.

Return vs Market: PCRX underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is PCRX's price volatile compared to industry and market?
PCRX volatility
PCRX Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: PCRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006697Dave Stackhttps://www.pacira.com

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure.

Pacira BioSciences, Inc. Fundamentals Summary

How do Pacira BioSciences's earnings and revenue compare to its market cap?
PCRX fundamental statistics
Market CapUS$1.81b
Earnings (TTM)US$20.88m
Revenue (TTM)US$654.06m

86.6x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PCRX income statement (TTM)
RevenueUS$654.06m
Cost of RevenueUS$233.10m
Gross ProfitUS$420.96m
Other ExpensesUS$400.08m
EarningsUS$20.88m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.46
Gross Margin64.36%
Net Profit Margin3.19%
Debt/Equity Ratio97.1%

How did PCRX perform over the long term?

See historical performance and comparison